MCID: BRS044
MIFTS: 58

Breast Adenocarcinoma

Categories: Rare diseases, Reproductive diseases, Cancer diseases

Aliases & Classifications for Breast Adenocarcinoma

MalaCards integrated aliases for Breast Adenocarcinoma:

Name: Breast Adenocarcinoma 12 28 14 69
Mammary Adenocarcinoma 12 69
Adenocarcinoma of Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3458
NCIt 46 C5214

Summaries for Breast Adenocarcinoma

Disease Ontology : 12 A breast carcinoma that originates in the milk ducts and/or lobules (glandular tissue) of the breast.

MalaCards based summary : Breast Adenocarcinoma, also known as mammary adenocarcinoma, is related to adenocarcinoma and squamous cell carcinoma. An important gene associated with Breast Adenocarcinoma is RB1CC1 (RB1 Inducible Coiled-Coil 1), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Paclitaxel and Letrozole have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Breast Adenocarcinoma

Diseases in the Breast Adenocarcinoma family:

Rare Adenocarcinoma of the Breast

Diseases related to Breast Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 152)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 31.6 CDKN1A EGF EGFR ERBB2 TP53
2 squamous cell carcinoma 29.8 CDKN1A EGF EGFR ERBB2 MMP9 TP53
3 fibrosarcoma 29.6 CDKN1A MMP9 PLAU TNF
4 neuroblastoma 29.4 CASP8 CASP9 CYCS PARP1 TP53
5 hepatocellular carcinoma 28.6 BAX CASP8 CASP9 CDKN1A CYCS EGFR
6 prostate cancer 27.7 BAX CASP8 CASP9 CDKN1A CYCS EGF
7 colorectal cancer 27.2 BAX CASP8 CASP9 CDKN1A CYCS EGF
8 vestibular gland benign neoplasm 10.6 ESR1 TP53
9 endometrial clear cell adenocarcinoma 10.6 ESR1 TP53
10 bartholin's gland adenoma 10.6 ESR1 TP53
11 glassy cell carcinoma of the cervix 10.6 ERBB2 ESR1
12 breast intraductal proliferative lesion 10.6 EGFR ERBB2
13 adult hepatocellular carcinoma 10.6 CASP8 EGF TP53
14 brain ependymoma 10.6 EGFR TP53
15 breast benign neoplasm 10.6 ERBB2 ESR1 TP53
16 thoracic benign neoplasm 10.6 ERBB2 ESR1 TP53
17 uterine corpus cancer 10.6 ERBB2 ESR1 TP53
18 mixed cell type cancer 10.6 ERBB2 ESR1 TP53
19 fallopian tube carcinoma 10.6 ERBB2 ESR1 TP53
20 microglandular adenosis 10.6 EGFR ERBB2 TP53
21 breast scirrhous carcinoma 10.6 EGFR ERBB2 ESR1
22 suppressor of tumorigenicity 3 10.6 BAX CDKN1A TP53
23 oncocytic breast carcinoma 10.6 EGFR ERBB2 ESR1
24 sweat gland cancer 10.6 ERBB2 ESR1 TP53
25 estrogen-receptor negative breast cancer 10.6 EGF ERBB2 ESR1
26 breast adenoid cystic carcinoma 10.5 EGFR ERBB2 ESR1
27 female breast cancer 10.5 ERBB2 ESR1 TP53
28 pigmented villonodular synovitis 10.5 MMP9 TNFSF11 TP53
29 luminal breast carcinoma 10.5 EGFR ERBB2 ESR1
30 breast carcinoma in situ 10.5 ERBB2 ESR1 TP53
31 uterine carcinosarcoma 10.5 EGFR ERBB2 TP53
32 cholesteatoma of middle ear 10.5 EGF MMP9 TNFSF11
33 primary peritoneal carcinoma 10.5 EGFR ERBB2 TP53
34 inflammatory breast carcinoma 10.5 EGFR ERBB2 ESR1
35 small intestinal adenocarcinoma 10.5 BAX EGFR ERBB2
36 lipid-rich carcinoma 10.5 EGFR ERBB2 ESR1
37 keratocystic odontogenic tumor 10.5 MMP9 TNFSF11 TP53
38 endometrial adenosquamous carcinoma 10.5 EGF PLAU
39 mammary paget's disease 10.5 EGFR ERBB2 ESR1
40 cheilitis 10.5 CDKN1A MMP9 TP53
41 tubular adenocarcinoma 10.5 EGFR ERBB2 ESR1
42 sporadic breast cancer 10.5 ERBB2 ESR1 TP53
43 triple-receptor negative breast cancer 10.5 ERBB2 ESR1 PARP1
44 pharynx cancer 10.5 EGFR MMP9 TP53
45 autonomic nervous system neoplasm 10.5 CASP8 CYCS TP53
46 carbuncle 10.5 BAX CASP9 CYCS
47 actinic cheilitis 10.5 CDKN1A TNF TP53
48 intracystic papillary adenoma 10.5 EGFR ERBB2
49 tongue cancer 10.5 CDKN1A MMP9 TP53
50 soft tissue sarcoma 10.5 EGFR TNF TP53

Graphical network of the top 20 diseases related to Breast Adenocarcinoma:



Diseases related to Breast Adenocarcinoma

Symptoms & Phenotypes for Breast Adenocarcinoma

GenomeRNAi Phenotypes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 TP53 BAX CASP8 CASP9 CDKN1A SLC22A18
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 TP53 BAX CASP8 CASP9 CDKN1A SLC22A18

MGI Mouse Phenotypes related to Breast Adenocarcinoma:

43 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.54 TP53 CYCS CTSK EGFR BAX CASP9
2 growth/size/body region MP:0005378 10.53 TP53 TNFSF11 EGF CTSK EGFR CYCS
3 hematopoietic system MP:0005397 10.49 TP53 TNFSF11 CTSK EGFR CYCS BAX
4 immune system MP:0005387 10.49 TP53 TNFSF11 EGF CTSK EGFR CYCS
5 endocrine/exocrine gland MP:0005379 10.46 TP53 TNFSF11 CYCS EGF CTSK EGFR
6 homeostasis/metabolism MP:0005376 10.45 TP53 TNFSF11 CDKN1A CTSK CASP8 BAX
7 behavior/neurological MP:0005386 10.4 TNFSF11 TNF TP53 CYCS CDKN1A BAX
8 cardiovascular system MP:0005385 10.4 TNF TP53 CDKN1A CYCS CASP8 CASP9
9 integument MP:0010771 10.4 TP53 TNFSF11 EGF EGFR CDKN1A CASP8
10 mortality/aging MP:0010768 10.38 TNF TP53 TNFSF11 CDKN1A CYCS CASP8
11 craniofacial MP:0005382 10.35 TP53 TNFSF11 CYCS CTSK CDKN1A CASP9
12 digestive/alimentary MP:0005381 10.34 TP53 CDKN1A EGF CTSK ERBB2 EGFR
13 embryo MP:0005380 10.33 TNF TP53 CDKN1A CYCS CASP8 CASP9
14 nervous system MP:0003631 10.28 TP53 CYCS CTSK CDKN1A CASP8 BAX
15 limbs/digits/tail MP:0005371 10.25 TP53 TNFSF11 CTSK EGFR BAX CDKN1A
16 neoplasm MP:0002006 10.25 TP53 TNFSF11 EGFR BAX CDKN1A CASP8
17 adipose tissue MP:0005375 10.23 TNF TP53 CDKN1A CTSK ESR1 EGFR
18 muscle MP:0005369 10.23 TP53 TNFSF11 CDKN1A CASP8 BAX ERBB2
19 liver/biliary system MP:0005370 10.15 TNF TP53 CDKN1A CASP8 ESR1 EGFR
20 hearing/vestibular/ear MP:0005377 10.11 TP53 CDKN1A BAX EGFR FOS PLAU
21 reproductive system MP:0005389 10.07 TP53 TNFSF11 EGF CDKN1A BAX ERBB2
22 no phenotypic analysis MP:0003012 9.97 TNFSF11 TNF TP53 CDKN1A EGFR ESR1
23 respiratory system MP:0005388 9.97 TP53 TNFSF11 CTSK EGFR BAX CASP9
24 renal/urinary system MP:0005367 9.92 TP53 CDKN1A CASP8 BAX ESR1 EGFR
25 skeleton MP:0005390 9.77 TP53 TNFSF11 CYCS CTSK CDKN1A BAX
26 vision/eye MP:0005391 9.36 TP53 TNFSF11 CDKN1A EGF BAX EGFR

Drugs & Therapeutics for Breast Adenocarcinoma

Drugs for Breast Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 2, Phase 3, Phase 1 33069-62-4 36314
2
Letrozole Approved, Investigational Phase 3,Phase 2 112809-51-5 3902
3
Tamoxifen Approved Phase 3 10540-29-1 2733526
4
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
5
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
6
Trastuzumab Approved, Investigational Phase 3,Phase 2 180288-69-1 9903
7
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 38904 498142
8
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
9
Exemestane Approved, Investigational Phase 3,Phase 2 107868-30-4 60198
10
Zoledronic acid Approved Phase 3 118072-93-8 68740
11
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
13 Albumin-Bound Paclitaxel Phase 2, Phase 3, Phase 1
14 Antimitotic Agents Phase 2, Phase 3, Phase 1
15 Antineoplastic Agents, Phytogenic Phase 2, Phase 3, Phase 1
16 Antirheumatic Agents Phase 3,Phase 2,Phase 1
17 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
18 Anticoagulants Phase 3
19 Antineoplastic Agents, Hormonal Phase 3,Phase 2
20 Aromatase Inhibitors Phase 3,Phase 2
21 Bone Density Conservation Agents Phase 3
22 Calcium, Dietary Phase 3
23 Chelating Agents Phase 3
24 Estrogen Antagonists Phase 3,Phase 2
25 Estrogen Receptor Modulators Phase 3
26 Estrogens Phase 3,Phase 2,Phase 1
27 Hormone Antagonists Phase 3,Phase 2
28 Hormones Phase 3,Phase 2
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
30 Selective Estrogen Receptor Modulators Phase 3
31 Steroid Synthesis Inhibitors Phase 3,Phase 2
32 Alkylating Agents Phase 3,Phase 2,Phase 1
33 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
34 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
35 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
36 Diphosphonates Phase 3
37 Citrate Nutraceutical Phase 3
38
Hydroxychloroquine Approved Phase 2 118-42-3 3652
39
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
40
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
41
Sulindac Approved, Investigational Phase 2 38194-50-2 1548887 5352
42
Aldesleukin Approved Phase 1, Phase 2 110942-02-4, 85898-30-2
43
Epirubicin Approved Phase 2 56420-45-2 41867
44
Testosterone Approved, Investigational Phase 2 58-22-0 6013
45
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
46
Fulvestrant Approved, Investigational Phase 2 129453-61-8 17756771 104741
47
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286 11431660 5005498
48
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
49
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
50
Pembrolizumab Approved Phase 2,Phase 1,Early Phase 1 1374853-91-4

Interventional clinical trials:

(show top 50) (show all 52)

# Name Status NCT ID Phase Drugs
1 Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer Completed NCT00949598 Phase 3 letrozole;tamoxifen citrate
2 A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer Recruiting NCT03337724 Phase 2, Phase 3 Ipatasertib;Paclitaxel;Placebo
3 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02488967 Phase 3 Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel
4 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Active, not recruiting NCT00869206 Phase 3 zoledronic acid
5 Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Active, not recruiting NCT00310180 Phase 3 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate
6 Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer Active, not recruiting NCT00005970 Phase 3 Aromatase Inhibition Therapy;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Tamoxifen Citrate
7 Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients Unknown status NCT01292408 Phase 2 Hydrochloroquine
8 Study of MDX-010 in Stage IV Breast Cancer Completed NCT00083278 Phase 2 MDX-010
9 Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer Completed NCT02063893 Phase 1, Phase 2
10 Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer Completed NCT00039520 Phase 2 docetaxel;sulindac
11 Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer Completed NCT00019916 Phase 1, Phase 2
12 Chemotherapy in Treating Women With Metastatic Breast Cancer Completed NCT00004046 Phase 2 exatecan mesylate
13 A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer Completed NCT02301988 Phase 2 Ipatasertib;Paclitaxel;Placebo
14 Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes Completed NCT01693549 Phase 2 Cabazitaxel
15 Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer Completed NCT00054301 Phase 2
16 Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility Completed NCT00591851 Phase 2 AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)
17 CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer Recruiting NCT02067741 Phase 2 CR1447
18 IMP321 as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma Recruiting NCT02614833 Phase 2 Placebo;Paclitaxel
19 Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer Recruiting NCT01928589 Phase 1, Phase 2
20 Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant Recruiting NCT02894398 Phase 2 Palbociclib;Letrozole;Anastrozole;Exemestane;Fulvestrant
21 A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread Recruiting NCT02322814 Phase 2 Cobimetinib;Paclitaxel;Placebo;Atezolizumab;Nab-Paclitaxel
22 Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Recruiting NCT02957968 Phase 2 Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab
23 Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer Recruiting NCT01697293 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Triciribine Phosphate
24 Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer Recruiting NCT01730833 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
25 Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation Recruiting NCT01245712 Phase 2
26 Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer Recruiting NCT02530489 Phase 2 MPDL3280A;Nab-paclitaxel
27 Neoadjuvant Talazoparib for Patients With a BRCA Deleterious Mutation Active, not recruiting NCT02282345 Phase 2 Talazoparib
28 Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 Active, not recruiting NCT01593020 Phase 2 Paclitaxel;Eribulin;5-Fluorouracil;Epirubicin;Cyclophosphamide;Doxorubicin
29 Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer Suspended NCT03106415 Phase 1, Phase 2 Binimetinib
30 Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer Terminated NCT00074269 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methotrexate
31 Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer Unknown status NCT00009763 Phase 1 cyclosporine;paclitaxel
32 Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast Completed NCT02204046 Phase 1 BIWA 4
33 Vaccine Therapy in Treating Patients With Metastatic Breast Cancer Completed NCT00003761 Phase 1
34 Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer Completed NCT01502592 Phase 1
35 Clinical Trial of Trametes Versicolor in Women With Breast Cancer Completed NCT00680667 Phase 1
36 Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer Recruiting NCT02824575 Phase 1 Rebastinib;Paclitaxel;Eribulin Mesylate
37 Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM) Recruiting NCT01724606 Phase 1 Sorafenib
38 Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer Recruiting NCT02453620 Phase 1 Entinostat
39 Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors Recruiting NCT03102320 Phase 1 Cisplatin;Gemcitabine;Anetumab ravtansine (BAY94-9343)
40 Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Not yet recruiting NCT03432741 Phase 1 Belinostat;Carfilzomib;Fludeoxyglucose F-18;Gemcitabine Hydrochloride;Romidepsin
41 Vaccine Therapy in Treating Patients With Metastatic Breast Cancer Terminated NCT00071942 Phase 1
42 Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas Unknown status NCT01942629
43 Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility Completed NCT00617370 epirubicin, cyclophosphamide, Paclitaxel,
44 Radiation Therapy Followed by Surgery in Treating Patients With Early-Stage Breast Cancer Completed NCT01024582
45 Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI Recruiting NCT02306538
46 Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer Recruiting NCT03137693
47 Engineering Gut Microbiome to Target Breast Cancer Recruiting NCT03358511
48 Older Breast Cancer Patients: Risk for Cognitive Decline Recruiting NCT03451383
49 Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer Recruiting NCT02515110
50 Pilot; Open Label; Breast Cancer; Preoperative Pembrolizumab + Radiation Recruiting NCT03366844 Early Phase 1 Pembrolizumab

Search NIH Clinical Center for Breast Adenocarcinoma

Genetic Tests for Breast Adenocarcinoma

Genetic tests related to Breast Adenocarcinoma:

# Genetic test Affiliating Genes
1 Breast Adenocarcinoma 28

Anatomical Context for Breast Adenocarcinoma

MalaCards organs/tissues related to Breast Adenocarcinoma:

38
Breast, Brain, Bone, Prostate, Testes, Lung, Pancreas

Publications for Breast Adenocarcinoma

Articles related to Breast Adenocarcinoma:

(show top 50) (show all 315)
# Title Authors Year
1
Chitosan-Cellulose Multifunctional Hydrogel Beads: Design, Characterization and Evaluation of Cytocompatibility with Breast Adenocarcinoma and Osteoblast Cells. ( 29315214 )
2018
2
Lycopene-rich extract from red guava (Psidium guajava L.) displays cytotoxic effect against human breast adenocarcinoma cell line MCF-7 via an apoptotic-like pathway. ( 29433206 )
2018
3
Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study. ( 29138806 )
2018
4
Spheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro. ( 28461972 )
2017
5
Vanadium(III)-l-cysteine enhances the sensitivity of murine breast adenocarcinoma cells to cyclophosphamide by promoting apoptosis and blocking angiogenesis. ( 28466788 )
2017
6
Nanocapsules for the co-delivery of selol and doxorubicin to breast adenocarcinoma 4T1 cells in vitro. ( 29179603 )
2017
7
Phenolics from Rubus fairholmianus induces cytotoxicity and apoptosis in human breast adenocarcinoma cells. ( 28803117 )
2017
8
hsa-miR-1973 MicroRNA is Significantly and Differentially Expressed in MDA-MB-231 Cells of Breast Adenocarcinoma and Xenografts Derived from the Tumor. ( 28948560 )
2017
9
The effects of non-invasive radiofrequency electric field hyperthermia on biotransport and biodistribution of fluorescent [60]fullerene derivative in a murine orthotopic model of breast adenocarcinoma. ( 28527736 )
2017
10
Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue. ( 29147603 )
2017
11
Biotransport kinetics and intratumoral biodistribution of malonodiserinolamide-derivatized [60]fullerene in a murine model of breast adenocarcinoma. ( 29180866 )
2017
12
Persian Gulf Jellyfish (Cassiopea andromeda) Venom Fractions Induce Selective Injury and Cytochrome C Release in Mitochondria Obtained from Breast Adenocarcinoma Patients ( 28240847 )
2017
13
Evaluation of the Anticancer Activities of the Plant Alkaloids Sanguinarine and Chelerythrine in Human Breast Adenocarcinoma Cells. ( 28270066 )
2017
14
HER2/Topoisomerase IIa co-amplified breast adenocarcinoma "mirror" cases with different Topoisomerase IIa expression patterns. ( 28534385 )
2017
15
Efficient T3P(Ar) mediated synthesis, differential cytotoxicity and apoptosis induction by indolo-triazolo-thiadiazoles in human breast adenocarcinoma cells. ( 28235427 )
2017
16
Remote Development of Tumor-to-Tumor Metastasis of Breast Adenocarcinoma in a Renal Oncocytoma. ( 28551171 )
2017
17
Therapeutic effects of bach1 siRNA on human breast adenocarcinoma cell line. ( 28092843 )
2017
18
The application of the linear quadratic model to compensate the effects of prolonged fraction delivery time on a Balb/C breast adenocarcinoma tumor: An in vivo study. ( 26630280 )
2016
19
Role of Glutathione System Redox Potential in Apoptosis Dysregulation in MCF-7 Breast Adenocarcinoma. ( 26750929 )
2016
20
Ultrastructural Assessment of 2-(acridin-9-ylmethylene)-N-phenylhydrazinecarbothioamide activity on human breast adenocarcinoma cells. ( 27668344 )
2016
21
Ajwa Date (Phoenix dactylifera L.) Extract Inhibits Human Breast Adenocarcinoma (MCF7) Cells In Vitro by Inducing Apoptosis and Cell Cycle Arrest. ( 27441372 )
2016
22
Anti-proliferative and apoptosis inducing potential of hydroalcoholic Achillea wilhelmsii C. Koch extract on human breast adenocarcinoma cell lines MCF-7 and MDA-Mb-468. ( 28167484 )
2016
23
Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study. ( 27338760 )
2016
24
SERS-active Au/SiO2 clouds in powder for rapid ex vivo breast adenocarcinoma diagnosis. ( 27375955 )
2016
25
Fas-associated protein with death domain (FADD) regulates autophagy through promoting the expression of Ras homolog enriched in brain (Rheb) in human breast adenocarcinoma cells. ( 27013580 )
2016
26
Inhibitory and Cytotoxic Activities of Chrysin on Human Breast Adenocarcinoma Cells by Induction of Apoptosis. ( 27761071 )
2016
27
Mitochondrial thiol modification by a targeted electrophile inhibits metabolism in breast adenocarcinoma cells by inhibiting enzyme activity and protein levels. ( 26774751 )
2016
28
Phyto-synthesis of silver nanoparticles using Alternanthera tenella leaf extract: an effective inhibitor for the migration of human breast adenocarcinoma (MCF-7) cells. ( 26801668 )
2016
29
A Bowman-Birk inhibitor induces apoptosis in human breast adenocarcinoma through mitochondrial impairment and oxidative damage following proteasome 20S inhibition. ( 27551492 )
2016
30
In vitro cytotoxic effect of tyrosine kinase inhibitor sunitinib malate alone and in combination with hyperthermia on breast adenocarcinoma MCF-7 cells. ( 27569072 )
2016
31
Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alpha-irradiation combined with inhibitors of immunosuppression and CpG. ( 27495172 )
2016
32
Cambogin exerts anti-proliferative and pro-apoptotic effects on breast adenocarcinoma through the induction of NADPH oxidase 1 and the alteration of mitochondrial morphology and dynamics. ( 27418140 )
2016
33
Silencing of High Mobility Group Isoform I-C (HMGI-C) Enhances Paclitaxel Chemosensitivity in Breast Adenocarcinoma Cells (MDA-MB-468). ( 27478778 )
2016
34
Correction for Upadhyay et al., Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain. ( 26884179 )
2016
35
Cytotoxicity of Manganese (III) Complex in Human Breast Adenocarcinoma Cell Line Is Mediated by the Generation of Reactive Oxygen Species Followed by Mitochondrial Damage. ( 27461214 )
2016
36
Microbial-catalysed derivatization of anti-cancer drug exemestane and cytotoxicity of resulting metabolites against human breast adenocarcinoma cell line (MCF-7) in vitro. ( 27521799 )
2016
37
184AA3: a xenograft model of ER+ breast adenocarcinoma. ( 26661596 )
2016
38
Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation. ( 26802496 )
2016
39
Aldehyde dehydrogenase 3A1 promotes multi-modality resistance and alters gene expression profile in human breast adenocarcinoma MCF-7 cells. ( 27276244 )
2016
40
Synthesis of polydopamine as a new and biocompatible coating of magnetic nanoparticles for delivery of doxorubicin in mouse breast adenocarcinoma. ( 27752764 )
2016
41
HMGI-C suppressing induces P53/caspase9 axis to regulate apoptosis in breast adenocarcinoma cells. ( 27245202 )
2016
42
Oxidative modification induced by photodynamic therapy with PhotofrinArII and 2-methoxyestradiol in human ovarian clear carcinoma (OvBH-1) and human breast adenocarcinoma (MCF-7) cells. ( 25960212 )
2015
43
Anticancer Activity of Curcumin on Human Breast Adenocarcinoma: Role of Mcl-1 Gene. ( 26413251 )
2015
44
RSK4 knockdown promotes proliferation, migration and metastasis of human breast adenocarcinoma cells. ( 26397146 )
2015
45
Targeting Cellular Metabolism Chemosensitizes the Doxorubicin-Resistant Human Breast Adenocarcinoma Cells. ( 26558272 )
2015
46
Internalization and Recycling of the HER2 Receptor on Human Breast Adenocarcinoma Cells Treated with Targeted Phototoxic Protein DARPinminiSOG. ( 26483969 )
2015
47
Evaluation of fractionated and repeated sonodynamic therapy by using dual frequency for murine model of breast adenocarcinoma. ( 26124951 )
2015
48
Enhanced cytotoxicity in triple-negative and estrogen receptora89positive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel. ( 26178079 )
2015
49
Quercetin protects necrotic insult and promotes apoptosis by attenuating the expression of RAGE and its ligand HMGB1 in human breast adenocarcinoma cells. ( 25983116 )
2015
50
Sonochemotherapy of breast adenocarcinoma: an experimental in vivo model. ( 26191104 )
2015

Variations for Breast Adenocarcinoma

ClinVar genetic disease variations for Breast Adenocarcinoma:

6 (show all 11)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
2 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
3 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
4 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
5 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
6 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
7 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
8 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
9 RB1CC1 NG_015833.1: g.34008_95699del61692 deletion Pathogenic GRCh38 Chromosome 8, 52623768: 52685459
10 RB1CC1 NG_015833.1: g.57807_94706del36900 deletion Pathogenic GRCh38 Chromosome 8, 52624761: 52661660
11 SLC22A18 NM_002555.5(SLC22A18): c.864_865insNC_000011.10: g.2919738_2919848 insertion Pathogenic

Expression for Breast Adenocarcinoma

Search GEO for disease gene expression data for Breast Adenocarcinoma.

Pathways for Breast Adenocarcinoma

Pathways related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 129)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.16 CASP8 CASP9 CDKN1A CTSK EGF EGFR
2
Show member pathways
13.99 BAX CASP8 CASP9 CYCS EGF EGFR
3
Show member pathways
13.91 BAX CASP8 CASP9 CDKN1A CYCS EGF
4
Show member pathways
13.79 BAX CASP8 CASP9 CDKN1A EGF EGFR
5
Show member pathways
13.53 BAX CASP9 CDKN1A EGF EGFR ERBB2
6
Show member pathways
13.49 CDKN1A EGF EGFR ERBB2 FOS MMP9
7
Show member pathways
13.44 BAX CASP8 CASP9 EGF EGFR ERBB2
8
Show member pathways
13.39 CASP8 EGF EGFR ERBB2 ESR1 FOS
9
Show member pathways
13.34 BAX CYCS EGF EGFR ERBB2 FOS
10
Show member pathways
13.1 BAX CASP9 CDKN1A CYCS EGF EGFR
11
Show member pathways
13.09 BAX CASP8 CASP9 CDKN1A EGF EGFR
12
Show member pathways
13 CASP8 CASP9 CYCS EGFR FOS TNF
13
Show member pathways
13 BAX CASP8 CASP9 CYCS MMP9 PARP1
14
Show member pathways
12.93 CASP8 CASP9 CYCS FOS TNF TP53
15 12.9 CASP8 CASP9 EGF EGFR FOS TNF
16
Show member pathways
12.86 CASP9 CDKN1A EGF EGFR ERBB2 TP53
17
Show member pathways
12.83 BAX CASP9 CYCS ERBB2 ESR1 FOS
18
Show member pathways
12.79 CASP8 CDKN1A ESR1 PARP1 TP53
19
Show member pathways
12.79 CASP8 CASP9 CYCS EGFR FOS PARP1
20
Show member pathways
12.78 EGF EGFR FOS TNF TP53
21
Show member pathways
12.77 BAX CASP8 CASP9 CDKN1A CTSK CYCS
22
Show member pathways
12.75 CASP8 CASP9 CYCS FOS TNF TNFSF11
23
Show member pathways
12.69 BAX CASP9 CYCS EGF EGFR
24
Show member pathways
12.68 BAX CASP9 CDKN1A EGFR ERBB2 FOS
25 12.67 CDKN1A EGFR ERBB2 MMP9 PLAU TP53
26
Show member pathways
12.66 BAX CDKN1A EGFR ERBB2 ESR1 FOS
27
Show member pathways
12.65 CASP8 CASP9 CYCS FOS PARP1 TNF
28
Show member pathways
12.63 CDKN1A EGF EGFR ERBB2 FOS TP53
29
Show member pathways
12.62 BAX CDKN1A EGF EGFR ERBB2 ESR1
30
Show member pathways
12.61 BAX ERBB2 ESR1 FOS TNFSF11
31
Show member pathways
12.61 CASP8 CASP9 EGF EGFR ERBB2 FOS
32
Show member pathways
12.59 BAX CASP8 CASP9 EGFR ERBB2 TP53
33
Show member pathways
12.58 BAX CASP8 CASP9 CDKN1A CYCS FOS
34 12.56 BAX CDKN1A FOS TNF TP53
35
Show member pathways
12.53 BAX CASP9 CDKN1A FOS TP53
36
Show member pathways
12.49 CASP9 ESR1 FOS PLAU
37
Show member pathways
12.49 BAX CASP8 CASP9 CDKN1A CYCS TP53
38
Show member pathways
12.46 CASP9 EGF EGFR FOS
39
Show member pathways
12.43 CASP8 FOS MMP9 TNF
40
Show member pathways
12.42 EGF EGFR ERBB2 ESR1
41 12.4 BAX CASP8 CDKN1A TP53
42
Show member pathways
12.4 CASP8 CASP9 CYCS FOS TNF
43 12.4 BAX CDKN1A MMP9 PLAU TP53
44
Show member pathways
12.39 BAX CASP8 CASP9 CYCS PARP1 TNF
45
Show member pathways
12.39 BAX CASP8 CASP9 CDKN1A FOS TP53
46 12.38 BAX CASP8 CASP9 CYCS TNF
47
Show member pathways
12.37 BAX CASP9 CDKN1A EGFR ERBB2 TP53
48 12.34 CDKN1A EGFR ERBB2 ESR1 MMP9 PLAU
49
Show member pathways
12.33 BAX CASP8 PARP1 TNF
50 12.3 EGF EGFR ERBB2 FOS

GO Terms for Breast Adenocarcinoma

Cellular components related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.17 CASP8 CASP9 CDKN1A EGFR ESR1 PARP1

Biological processes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 9.98 EGF EGFR MMP9 PLAU
2 aging GO:0007568 9.97 CASP9 FOS NQO1 TP53
3 cellular response to organic cyclic compound GO:0071407 9.87 CASP8 CASP9 TNF
4 apoptotic signaling pathway GO:0097190 9.87 BAX CASP8 TNF
5 positive regulation of JNK cascade GO:0046330 9.87 RB1CC1 TNF TNFSF11
6 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.85 BAX CDKN1A TP53
7 response to toxic substance GO:0009636 9.85 BAX CDKN1A FOS NQO1
8 positive regulation of protein phosphorylation GO:0001934 9.85 EGFR ERBB2 MMP9 RB1CC1 TNF
9 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.84 BAX CASP9 TNF
10 positive regulation of fibroblast proliferation GO:0048146 9.83 CDKN1A EGFR ESR1
11 response to UV GO:0009411 9.83 CASP9 CDKN1A TP53
12 cellular response to UV GO:0034644 9.83 BAX CASP9 TP53
13 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.83 BAX CASP8 CASP9 TNF
14 positive regulation of protein kinase B signaling GO:0051897 9.83 EGF EGFR ERBB2 TNF TNFSF11
15 protein kinase B signaling GO:0043491 9.81 CASP9 CDKN1A TNF
16 extrinsic apoptotic signaling pathway GO:0097191 9.8 BAX CASP8 TNF
17 ERBB2 signaling pathway GO:0038128 9.8 EGF EGFR ERBB2
18 response to gamma radiation GO:0010332 9.78 BAX PARP1 TP53
19 response to antibiotic GO:0046677 9.77 CASP8 CASP9 TP53
20 positive regulation of neuron death GO:1901216 9.77 CASP8 FOS PARP1
21 cellular response to cadmium ion GO:0071276 9.76 EGFR FOS MMP9
22 positive regulation of phosphorylation GO:0042327 9.75 EGF EGFR TNFSF11
23 regulation of cell motility GO:2000145 9.74 EGF EGFR ERBB2
24 positive regulation of release of cytochrome c from mitochondria GO:0090200 9.73 BAX MMP9 TP53
25 positive regulation of catenin import into nucleus GO:0035413 9.71 EGF EGFR
26 positive regulation of osteoclast differentiation GO:0045672 9.71 FOS TNF TNFSF11
27 positive regulation of neuron apoptotic process GO:0043525 9.71 BAX CASP9 NQO1 TP53
28 vagina development GO:0060068 9.7 BAX ESR1
29 positive regulation of programmed cell death GO:0043068 9.7 CDKN1A TNF
30 response to salt stress GO:0009651 9.69 BAX TNF
31 mammary gland alveolus development GO:0060749 9.69 EGF ESR1 TNFSF11
32 death-inducing signaling complex assembly GO:0071550 9.68 CASP8 TNF
33 response to cobalt ion GO:0032025 9.67 CASP8 CASP9
34 macrophage differentiation GO:0030225 9.67 CASP8 MMP9 PARP1
35 negative regulation of ERBB signaling pathway GO:1901185 9.65 EGF EGFR ERBB2
36 response to estradiol GO:0032355 9.65 CASP8 CASP9 EGFR ESR1 NQO1
37 signal transduction by p53 class mediator GO:0072331 9.64 CDKN1A TP53
38 cellular response to reactive oxygen species GO:0034614 9.62 EGFR FOS MMP9 TP53
39 activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c GO:0008635 9.54 BAX CASP9 CYCS
40 intrinsic apoptotic signaling pathway GO:0097193 9.46 BAX CDKN1A CYCS TP53
41 positive regulation of MAP kinase activity GO:0043406 9.35 EGF EGFR ERBB2 TNF TNFSF11
42 response to organic cyclic compound GO:0014070 9.1 CASP9 CDKN1A EGFR FOS NQO1 TP53
43 positive regulation of transcription by RNA polymerase II GO:0045944 10.22 EGFR ESR1 FOS PARP1 TNF TNFSF11
44 apoptotic process GO:0006915 10.15 BAX CASP8 CASP9 CYCS PARP1 TP53
45 positive regulation of transcription, DNA-templated GO:0045893 10.11 EGF EGFR ESR1 FOS TNF TP53
46 cellular response to DNA damage stimulus GO:0006974 10.1 BAX CASP9 CDKN1A PARP1 TP53
47 negative regulation of apoptotic process GO:0043066 10.09 CDKN1A EGFR MMP9 NQO1 RB1CC1 TP53
48 positive regulation of apoptotic process GO:0043065 10.04 BAX CASP9 MMP9 TNF TP53
49 regulation of apoptotic process GO:0042981 10.02 BAX CASP8 CASP9 ESR1 TP53

Molecular functions related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 9.72 CASP8 CDKN1A EGFR SLC22A18 TP53
2 protein phosphatase binding GO:0019903 9.65 EGFR ERBB2 TP53
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.61 EGF EGFR ERBB2
4 cysteine-type endopeptidase activity GO:0004197 9.58 CASP8 CASP9 CTSK
5 protein kinase binding GO:0019901 9.5 CASP9 CDKN1A EGFR ESR1 PARP1 RB1CC1
6 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.46 EGFR ERBB2
7 tumor necrosis factor receptor binding GO:0005164 9.43 CASP8 TNF TNFSF11
8 nitric-oxide synthase regulator activity GO:0030235 9.37 EGFR ESR1
9 identical protein binding GO:0042802 9.32 BAX CASP8 EGFR ERBB2 ESR1 MMP9
10 protein binding GO:0005515 10.13 BAX CASP8 CASP9 CDKN1A CTSK CYCS

Sources for Breast Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....